Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., September 18, 2017 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating

inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public

offering. Aldeyra also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering, at the public offering price, less the

underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by Aldeyra, with net proceeds

to be used for the continued development of Aldeyra s lead compound ADX-102 and other product candidates, as well as for debt maintenance, working capital and other general corporate purposes.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Laidlaw & Company (UK) Ltd. is acting as the lead

manager for the offering.

The shares of common stock described above are being offered by Aldeyra pursuant to a shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on September 1, 2015. A

preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC s web site at www.sec.gov. When available, copies of the preliminary prospectus supplement

relating to these securities may also be obtained by sending a request to: Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by telephone at (212)

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of

these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases

thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra s lead product candidate, ADX-102, is an aldehyde trap in development as topical eye drops for the treatment of

ocular inflammation. ADX-102 has now been tested in over 250 patients in Phase 2 clinical trials in dry eye disease, allergic conjunctivitis, and noninfectious anterior uveitis. A dermatologic form of ADX-102 is in late-stage clinical development

for the treatment of ichthyosis due to Sj gren-Larsson Syndrome, an inborn error of aldehyde metabolism. ADX-102 has not been approved for sale in the U.S. or elsewhere.

Safe Harbor Statement

This release contains

forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the public offering and the anticipated use of the proceeds thereof. These

forward-looking statements are subject to a number of risks, including the satisfaction of customary closing conditions related to the proposed public offering and the risk factors set forth from time to time in Aldeyra s SEC filings, including

but not limited to the risks that are described in the Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations sections of Aldeyra s Annual Report on Form 10-K for the year ended December 31, 2016 and Aldeyra s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, which are on file with the SEC and

available on the SEC s website at www.sec.gov. In addition to the risks described above and in Aldeyra s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra s results. No forward-looking

statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking

statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Aldeyra Therapeutics, Inc.

Tel: +1 781-761-4904 Ext. 205

Tel: +1 339-970-2843

MacDougall Biomedical Communications

Tel: +1 781-591-3443

Source: Aldeyra Therapeutics, Inc.